20 November, 2018 FDA Approves Gamifant® (emapalumab-lzsg), the First and Only Treatment Indicated for Primary Hemophagocytic Lymphohistiocytosis (HLH) 13 November, 2018 Sobi™ to acquire Synagis® US rights from AstraZeneca - creates a platform for global growth 20 July, 2018 Sobi strengthens inflammation franchise by acquiring global rights for emapalumab from Novimmune 17 April, 2018 Sobi Receives Approval from Health Canada for Once-Daily Dosing of Orfadin® (nitisinone) for the Treatment of HT-1 28 February, 2018 Sobi launches enhanced corporate sustainability initiative 27 February, 2018 Sobi’s Orfadin® (nitisinone) Receives Positive Reimbursement Recommendation for the Treatment of HT-1 from CADTH Canadian Drug Expert Committee 13 February, 2018 Sobi Names Linea Aspesi Vice President of Human Resources in North America 25 January, 2018 Sobi Names Holly May Vice President of Sales and Marketing in United States 23 January, 2018 FDA accepts investigational new drug application and grants Fast Track status for SOBI003 for the treatment of MPS IIIA 15 December, 2017 Sobi Launches Orfadin® (nitisinone) Ambassador Program to Support Patients and Caregivers Living with Hereditary Tyrosinemia Type 1 (HT-1) Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Current page 3 Page 4 Page 5 Next page Next › Last page Last »